Results 181 to 190 of about 3,811,568 (245)

Enzalutamide-Induced Host Metabolic Reprogramming Is Associated with Treatment Outcomes in Patients with Castration-Resistant Prostate Cancer: A Hypothesis-Generating Study. [PDF]

Clin Pharmacol Ther
Corona G, Visentin M, Samodelov SL, Maines F, Caffo O, Miolo G.   +5 more
europepmc   +1 more source

CDK9 degrader induces BRCAness and sensitizes castration-resistant prostate cancer to PARP inhibitor. [PDF]

Theranostics
Li J, Sun J, Tan W, Li G, Xiao W, Wu J, Yang W, Chen C, Li Y, Liu J, Liu Y, Liu D, Chen XH, Zhu R, Huang R, Yan J.   +15 more
europepmc   +1 more source

An assessment of time toxicity in patients receiving [177Lu]Lu-PSMA-617 for metastatic castration-resistant prostate cancer. [PDF]

Oncologist
Scharf Z, Muniz M, Tchitchkan E, Rami A, Ravi P, Orme JJ, Tarhini A, Jacene HA, Sentana-Lledo D, Childs DS.   +9 more
europepmc   +1 more source

Evaluation of the safety and efficacy of ²²⁵Ac-PSMA-CY313 in metastatic castration-resistant prostate cancer: preliminary results. [PDF]

Eur Radiol Exp
Zhang H, Shi Y, Yu Y, He Z, Luo F, Wu Y, Tang T, Ma D, Li S.   +8 more
europepmc   +1 more source

PU.1 is a mediator of the reactive stromal response associated with castration-resistant prostate cancer. [PDF]

Commun Biol
Bonollo F, Hanhart D, de Brot S, Cheng W, Chouvardas P, Roth B, Thalmann GN, Sampson N, Kruithof-de Julio M, Karkampouna S.   +9 more
europepmc   +1 more source

Update to "Renal and Multiorgan Safety of ¹⁷⁷Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer in the VISION Dosimetry Substudy". [PDF]

J Nucl Med
Herrmann K, Rahbar K, Eiber M, Sparks R, Baca N, Krause BJ, Lassmann M, Jentzen W, Tang J, Chicco D, Klein P, Blumenstein L, Basque JR, Kurth J.   +13 more
europepmc   +1 more source

Real-world treatment durability and pain management in older adults with metastatic castration-resistant prostate cancer. [PDF]

J Geriatr Oncol
Cobran EK, Afzal U, Mi L, Asiri IM.
europepmc   +1 more source

Novel risk scoring system for patients with metastatic castration-resistant prostate cancer treated with lutetium-177-PSMA-617. [PDF]

Oncologist
Gerke MB, Marra A, Jayaraj M, Yildrim A, Bedmutha A, Brown JT, Nazha B, Berchuck JE, Parikh RB, Ahmed S, Ciuro JA, Hartman C, McClintock GR, Caulfield S, Kucuk O, Carthon BC, Schuster DM, Muzahir S, Liu Y, Bilen MA.   +19 more
europepmc   +1 more source